Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine for ED Sedation in Older Adults
NCT06370442Phase 3Not yet recruiting
- Sponsor
- Upstate Medical University
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dexmedetomidine in Altered mental status (AMS) (3 arms), sponsored by Upstate Medical University. Primary endpoint: Sedation at 1 hour. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
Altered mental status (AMS)
Beyond the preview
Go deeper on NCT06370442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370442.